ABCA1 and metabolic dysfunction-associated steatotic liver disease: Clinical studies have found that ABCA1 levels in both NAFLD and DKD patients are significantly lower than in healthy patients, and that reduced ABCA1 expression is positively correlated with markers of progression in NAFLD and DKD 56-58.